Sign In
Buy KALV
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026
3 Micro-Cap Stocks That Could Be Moonshots
10:31pm, Tuesday, 14'th Nov 2023
Amid the valuations of large-cap stocks, notably tech stocks in the Magnificent 7 declining, this has led to this list of micro-cap stocks. Not only are investors expected to rotate into smaller and u
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
06:30am, Tuesday, 07'th Nov 2023
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializat
KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
06:30am, Thursday, 02'nd Nov 2023
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
KalVista's Sebetralstat: A Pill Worth Swallowing In HAE
12:05am, Sunday, 01'st Oct 2023
KalVista Pharmaceuticals is positioned to disrupt the HAE treatment landscape with its oral therapy, sebetralstat, offering rapid symptom relief and improved patient adherence. Financially, KalVista h
Is it a Good Idea to Invest in KalVista (KALV) Stock Now?
10:31am, Wednesday, 20'th Sep 2023
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now may turn out to be a prudent move now.
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
06:30am, Tuesday, 19'th Sep 2023
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializat
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
10:32am, Monday, 18'th Sep 2023
Innovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.
Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year?
11:18am, Wednesday, 06'th Sep 2023
Here is how KalVista Pharmaceuticals, Inc. (KALV) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 HAEi Regional Conference EMEA
06:30am, Monday, 28'th Aug 2023
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2023 US HAEA National Summit
06:30am, Friday, 14'th Jul 2023
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
KalVista (KALV) Surges 15% on Update From Angioedema Study
11:00am, Monday, 10'th Jul 2023
KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angioedema attacks. The stock rises 15% in response.
KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
06:30am, Friday, 02'nd Jun 2023
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference
06:30am, Wednesday, 31'st May 2023
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference
06:30am, Tuesday, 23'rd May 2023
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop
06:30am, Thursday, 27'th Apr 2023
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
